Clinical trials: Stage I Bladder Cancer
Bladder Cancer
Surgery and BCG in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00002990
- Testing
- BCG vaccine
- Where
- 40 sites in Austria, Belgium and 9 more
- Volunteers
- 1,288 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Urinary Bladder Neoplasms
Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Urinary Bladder Neoplasms.
- Trial name
- IRE (NCT02430623)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Bladder Cancer, Bladder Cancer Stage I
Loop Resection or Cold-cup Biopsy? A Study Comparing the Accuracy of Muscle Samples During Bladder Tumor Surgery
In this report the investigators compared two deep muscle sampling methods (Loop resection and Cold-Cup Biopsy) during endoscopic resection of bladder tumors for patients with suspected bladder cancer in Tygerberg hospital.
- Conditions
- Bladder Cancer, Bladder Cancer Stage I, TURBT
- Trial name
- NCT06796413
- Testing
- Loop Resection or Cold-cup biopsy
- Where
- South Africa
- Volunteers
- 120 people
- Sponsor
- University of Stellenbosch
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01090466
- Testing
- cisplatin, gemcitabine hydrochloride, temsirolimus
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cardiff University
Bladder Cancer, High-Risk Cancer
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
We will conduct a Phase I trial testing whether local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab in localized bladder cancer will stimulate an effective…
- Conditions
- Bladder Cancer, High-Risk Cancer, Tremelimumab, Durvalumab
- Trial name
- Rideau (NCT05120622)
- Testing
- Tremelimumab
- Where
- Canada
- Sponsor
- University of British Columbia
Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
This phase I trial studies the side effects and best dose of vaccine therapy given directly into the bladder in treating patients who are undergoing surgery to remove all or part of the bladder.
- Conditions
- Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma
- Trial name
- NCT00072137
- Testing
- Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002490
- Testing
- BCG vaccine, mitomycin C, radiation therapy
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer
This randomized phase II trial studies how well robotic radical cystectomy (RRC) or open radical cystectomy (ORC) works in treating patients with bladder cancer.
- Conditions
- Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
- Trial name
- NCT02699853
- Testing
- Questionnaire Administration, Radical Cystectomy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Southern California
Bladder Cancer
Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy drugs directly into the bladder may kill more cancer cells.
- Trial name
- NCT00042887
- Testing
- mitomycin C, conventional surgery
- Where
- 12 sites in Belgium, Italy and 3 more
- Volunteers
- 58 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Carcinoma, Breast Cancer
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Background: Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies.
- Conditions
- Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer
- Trial name
- NCT02457650
- Testing
- Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
Bladder Cancer
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
RATIONALE: Transurethral resection is a less invasive type of surgery for bladder cancer or benign prostatic hyperplasia. Transurethral resection using a loop resectoscope may have fewer side effects and improve recovery.
- Trial name
- NCT00303654
- Testing
- biopsy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roei Medical Technologies Ltd.
Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
- Trial name
- NCT00001381
- Testing
- suramin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Bladder Cancer, Stage 0 Bladder Cancer
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
This randomized clinical trial studies intracorporeal or extracorporeal urinary diversion during robotic assisted radical cystectomy in reducing complications in patients with bladder cancer.
- Conditions
- Recurrent Bladder Cancer, Stage 0 Bladder Cancer, Stage I Bladder Cancer, Stage II Bladder Cancer
- Trial name
- NCT02252393
- Testing
- robot-assisted laparoscopic surgery, intraoperative complication management/prevention, quality-of-life assessment
- Sponsor
- Case Comprehensive Cancer Center
Solid Tumor, Urethral Cancer
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or…
- Trial name
- NCT00479128
- Testing
- Bortezomib, Gemcitabine, Doxorubicin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Bladder Cancer
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005047
- Testing
- cisplatin, doxorubicin hydrochloride, methotrexate
- Where
- 74 sites in United States, Canada
- Volunteers
- 521 people
- Sponsor
- SWOG Cancer Research Network